VALIDATE Annual Meeting 2024 - Agenda

The Annual Meeting will be taking place in the Galaxy Room at the Avani+ Riverside Hotel, Bangkok, Thailand

0900 - 1000    Closed Network Management Board (NMB) & Scientific Advisory Board (SAB) Meeting  (Invitation only)

0915 - 1000    Registration & Tea/Coffee 

Image

1000 - 1015    Welcome

Prof Helen McShane, VALIDATE Network Director, University of Oxford, UK & Prof Narisara Chantratita, Mahidol University, Thailand

Image

1015 - 1035    VALIDATE Update

Mrs Samantha Vermaak, Co-Investigator & Executive Manager, University of Oxford, UK

Image

1035 - 1120    Navigating the Landscape: Understanding Melioidosis through Clinical Epidemiology, Immune Response Dynamics, and Diagnostic Innovations

Prof Narisara Chantratita, Mahidol University, Thailand

Image

1120 - 1140    Identifying Persister Mycobacterium tuberculosis Biosignatures

Dr Nastassja Kriel, Stellenbosch University, South Africa

Image

1140 - 1200    Evaluation of the Efficacy of BCGΔBCG1419c Vaccination Plus a Booster of EsxG/EsxH-derived Peptides to Prevent Tuberculosis Progression 

Dr Cristian Segura-Cerda, Centro de Investigación y Asistencia en Tecnología y Diseño de Jalisco (CIATEJ), Mexico

1200 - 1300        Lunch

Image

1300 - 1330   Different Adjuvants Significantly Influence the Immunogenicity and Protective Capacity of a Melioidosis Subunit Vaccine

Prof Mary Burtnick, University of Nevada, Reno School of Medicine, USA

Image

1330 - 1350 Alvacc A Human In Vitro Alveolus Model to Study Aerogenic TB Vaccine Binding and Translocation

Dr Diane Lee, University of Surrey, UK

Image

1350 - 1410    Towards a T-cell Subset that can Control Mycobacterium tuberculosis Infection

Dr Munyaradzi Musvosvi, University of Cape Town (UCT), South Africa

Image

1410 - 1430    Evaluation of BCGΔBCG1419cESAT6-PE25SS in Immunocompetent and Immunocompromised Mouse Models of TB  

Dr Ana Maria Valencia-Hernandez, James Cook University, Australia

Image

1430 - 1500    The Deletion of Interleukin-4 receptor alpha (IL-4Rα) Signalling on T cells Increased Host Susceptibility to TB

Dr Suraj Parihar, University of Cape Town (UCT), South Africa

1500 - 1530    Afternoon Break

Image

1530 - 1645    Your Chance to Meet Other VALIDATE Members

Attendees will get the chance to meet other VALIDATE members in this high-energy, quick-fire activity aimed at fostering community building and networking.

1645 - 1700    Day Wrap up

1700 - 1830    Drinks Reception / Poster Session (Moon Room)

1830 - 2120    Annual Meeting Dinner (Lunar Room)

Image

0900 - 0945    Lessons Learned in BP vs NTM Research

Asst Prof Ganjana Lertmemongkolchai, Chiang Mai University, Thailand

Image

0945 - 1000    Elucidating the Microbicidal and Regulatory Functions of Bovine Neutrophils During a Natural Mycobacterium bovis Infection

Dr Susana Flores-Villalva, INIFAP, Mexico

Image

1000 - 1015    Establishing the Immunogenicity of the First Naturally Presented Leishmania Epitope Vaccine Candidates in Ethiopian Cutaneous Leishmaniasis

Dr Thao-Thy Pham, Institute of Tropical Medicine Antwerp, Belgium

Image

1015 - 1030    Defining the Mechanism of BCG-Priming and its Impact on Subunit Vaccine Boosting

Dr Elena Stylianou, University of Oxford, UK

Image

1030 - 1100    "Mind the Gap" - Bridging Our Knowledge of Animal and Human Tuberculosis

Prof Michele Miller, Stellenbosch University, South Africa

1100 - 1130    Morning Break

Image

1130 - 1145    Innovative Diagnosis for PKDL/Leprosy Project Update 

Prof Mitali Chatterjee, Institute of Post-Graduate Medical Education and Research (IPGMER), India

Image

1145 - 1205    Towards a Better TB Vaccine Understanding Improved Local Immune Control by Mucosal BCG Vaccination

Dr Paula Niewold, Leiden University Medical Center (LUMC), Netherlands

Image

1205 - 1225    Testing a Novel, Self-adjuvanting Mucosal Vaccine Candidate for TB in the Mouse Model of Infection 

Dr Andy Tran, St George's University of London (SGUL), UK

Image

1225 - 1245    Characterising the Cytokines Associated with Trained Innate Immunity in BCG Vaccinated Non-human Primates

Dr Laura Sibley, UK Health Security Agency (UKHSA), UK

1245 - 1345    Lunch

Image

1530 - 1600    Therapeutics Informing Vaccine Development for Human Leishmaniasis

Dr Maria Adelaida Gomez, Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDEIM), Colombia  

Image

1415 - 1430    Evaluation of Recombinant Chimeric Protein Vaccine with Adjuvant Protection Against Visceral Leishmaniasis

Dr Daniela Pagliara Lage, Federal University of Minas Gerais, Brazil

Image

1445 - 1500    Translating protective immune signatures in the lung to peripheral biomarkers for TB

Dr Paula Niewold, Leiden University Medical Centre, Netherlands

Image

1430 - 1445    Probing Extreme Phenotypes to Determine Correlates of Risk for Recurrent TB: a Step Towards Optimised Vaccine Development

Dr Happy Tshivhula, Stellenbosch University, South Africa

1500 - 1530    Afternoon Break

Image

1530 - 1600    Defining Correlates of Humoral Immunity Against Inhalational Melioidosis

Prof Paul Brett, University of Nevada, USA;

Image

1600- 1630    Planning Phase I and Phase II vaccine trials: lessons from the past 30 years of human vaccine trials

Honorary Professor Allan Saul, The Burnet Institute / University of Melbourne, Australia

1630- 1645    Wrap-up and farewell